Targeted drug combo after focused radiation for CNS lymphoma
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of central nervous system (CNS) lymphoma, either primary (started in the brain or spinal cord) or secondary (spread from elsewhere).
- Your lymphoma must have returned or not responded to at least one treatment, OR you must be unable to receive a standard chemotherapy called high-dose methotrexate.
- You must be a candidate for a type of focused radiation called stereotactic radiosurgery (SRS). This means your brain lesions must be less than 6 cm, and you must have fewer than 10 lesions.
- You must have disease that can be seen on imaging (like MRI) or in the fluid around the brain and spinal cord (CSF).
- You must not have received radiation to the brain before, and you must not have had a donor stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests a new drug combination for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new drug, zanubrutinib, combined with standard chemotherapy for people recently diagnosed with primary central nervous system lymphoma (a type of brain cancer). It aims to see if this combination is safe and effective.
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
Hear when a new Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.